Јули КСНУМКС: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion in 2021 and is expected to register a revenue CAGR of 24.9 percent over the course of the forecast period. The rising incidence of cancer all over the world as well as the growing mortality rate caused by cancer are expected to be the primary drivers of revenue growth in the global CAR-T cell therapy market over the course of the forecast period. The expansion of clinical trial activities at a breakneck pace, the proliferation of mergers and acquisitions, and the allure of initial public offerings are all factors that are contributing to the growth of revenue in the global CAR T-cell therapy market.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global ЦАР Т-ћелијска терапија market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the ЦАР Т-ћелијска терапија market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Додатни значајни налази из извештаја указују на то
In 2021, the segment of diffuse large B-cell лимфом was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with терапија химерним антигенским рецептором Т-ћелија, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell не-Ходгкинови лимфоми who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Кључне компаније које тренутно послују на тржишту су даље истражене у овом извештају, као и њихови профили компанија, портфељи производа, стратегије ширења и стратешка савезништва. Неки примери ових врста савеза укључују спајања и аквизиције, сарадње и заједничка улагања. Поред тога, пружа нагласке о достигнућима и финансијском стању компаније, као и увид у тржишни домет и глобалну позицију компаније.
Компаније профилисане на глобалном тржишту ЦАР Т-ћелијске терапије:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Прочитајте више о глобалном извештају о тржишту ЦАР Т-Целл Тхерапи на: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
